That's what Piper said in march after Albuferon phasse III results:"We still forecast peak U.S. Albuferon sales of $919 million and global sales of $1.6 billion in 2014, however have flat lined our long-term market share at 35%."I'm searching for more forecasts. If anyone got more data, would be nice to share it.
Add another $1.5 billion from Benlysta, if phase III suceeds. We'll see where HGSI share price will be in 2 years.
Lukin_basher, read it again and again.
it says flat-lined. Just what this stock will do when lupus drug fails!
Why is no-one discussing the potential of Albuferon. $1.6 bln in sales or 35% market share is huge. Albuferon alone should justify $10.
35% market share of the multi billion hepatitis market would be great for HGSI, which is still trading around cash. HGSI's $380mln market cap is a joke, should be 10 times higher.
Only Albuferon justifies a share price of $5+, HGSI is sooooo cheap.